-
Mashup Score: 2Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma - Starton Therapeutics - 7 month(s) ago
Paramus, NJ – Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple myeloma […]
Source: www.startontx.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
🚨 NEWS 🚨 The first patient has been dosed in the phase Ib STAR-LLD clinical trial of low-dose lenalidomide, administered subcutaneously, for the treatment of multiple #myeloma Read more: https://t.co/gWiw67GUqI #mmsm #MedNews https://t.co/s4BRfIrxOy